Linked Data API

Show Search Form

Search Results

100186
star this property registered interest false more like this
star this property date less than 2014-10-21more like thismore than 2014-10-21
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Patients: Safety more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 211233 more like this
star this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2014-10-28more like thismore than 2014-10-28
unstar this property answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2014-10-28T15:28:25.797Zmore like thismore than 2014-10-28T15:28:25.797Z
star this property question first ministerially corrected
less than 2014-10-28T16:30:53.2329022Zmore like thismore than 2014-10-28T16:30:53.2329022Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property previous answer version
24770
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property answering member 3918
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
171817
star this property registered interest false more like this
star this property date less than 2015-01-02more like thismore than 2015-01-02
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis: Drugs more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what response he has made to the request by NHS England to defer implementation of the guidance on sofosbuvir for hepatitis C. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 219601 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-01-09more like thismore than 2015-01-09
unstar this property answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN 219602 more like this
star this property question first answered
less than 2015-01-09T14:33:04.703Zmore like thismore than 2015-01-09T14:33:04.703Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
171818
star this property registered interest false more like this
star this property date less than 2015-01-02more like thismore than 2015-01-02
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis: Drugs more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, when NICE guidance on the use of sofosbuvir for treating hepatitis C will be published. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 219602 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-01-09more like thismore than 2015-01-09
unstar this property answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN 219601 more like this
star this property question first answered
less than 2015-01-09T14:33:04.857Zmore like thismore than 2015-01-09T14:33:04.857Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
178985
star this property registered interest false more like this
star this property date less than 2015-02-10more like thismore than 2015-02-10
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, with reference to his Department's report, Hepatitis C in the UK, published in July 2014, what steps he is taking to approve for use new treatments for people with hepatitis C-related liver damage. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 223984 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-02-23more like thismore than 2015-02-23
unstar this property answer text <p>The Government is committed to ensuring that patients have access to clinically and cost effective treatments, including those for hepatitis C.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE is currently appraising a number of new drugs for use in the treatment of hepatitis C under its technology appraisal process. These are shown in the following table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Drug/indication</p></td><td><p>Expected date of final guidance</p></td></tr><tr><td><p>sofosbuvir (Sovaldi) for treating chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>simeprevir (Olysio) for treating genotype 1 or 4 chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C</p></td><td><p>June 2015</p></td></tr><tr><td><p>daclatasvir (Daklinza) for treating chronic hepatitis C</p></td><td><p>August 2015</p></td></tr><tr><td><p>ombitasvir/paritaprevir/ritonavir (Viekirax) with or without dasabuvir (Exviera) for treating chronic hepatitis C</p></td><td><p>September 2015</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>More generally, we have launched an Innovative Medicines and Medical Technology Review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The review will examine the pathway from ‘first in human’ trials, through licensing and health technology appraisal, to commissioning and clinical practice. It will set out both short and long-term options for action by Government and relevant bodies, including NICE, the Medicines and Healthcare products Regulatory Agency and NHS England, and mark a major contribution to the policy debate.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-02-23T16:20:22.74Zmore like thismore than 2015-02-23T16:20:22.74Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
225476
star this property registered interest false more like this
star this property date less than 2015-03-05more like thismore than 2015-03-05
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, which medicines his Department plans to include in the fast track interim policy for hepatitis C medicines. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 226494 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-03-12more like thismore than 2015-03-12
unstar this property answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
226492 more like this
226493 more like this
star this property question first answered
less than 2015-03-12T14:26:47.197Zmore like thismore than 2015-03-12T14:26:47.197Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
225477
star this property registered interest false more like this
star this property date less than 2015-03-05more like thismore than 2015-03-05
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, who his Department and NHS England have consulted on the implementation of a fast track interim policy for hepatitis C patients from April 2015. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 226492 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-03-12more like thismore than 2015-03-12
unstar this property answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
226493 more like this
226494 more like this
star this property question first answered
less than 2015-03-12T14:26:46.97Zmore like thismore than 2015-03-12T14:26:46.97Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
225478
star this property registered interest false more like this
star this property date less than 2015-03-05more like thismore than 2015-03-05
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what progress has been made on the delivery of a fast track interim policy for hepatitis C medicines for patients who need it from April 2015. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 226493 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-03-12more like thismore than 2015-03-12
unstar this property answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
226492 more like this
226494 more like this
star this property question first answered
less than 2015-03-12T14:26:47.097Zmore like thismore than 2015-03-12T14:26:47.097Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
228171
star this property registered interest false more like this
star this property date less than 2015-03-18more like thismore than 2015-03-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Inflammatory Bowel Disease more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what funding there has been from the public purse for research into treatment of (a) Crohn's disease and (b) ulcerative colitis in the last five years. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 228177 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-03-25more like thismore than 2015-03-25
unstar this property answer text <p>The following table shows expenditure on research relating to the treatment of Crohn’s disease and ulcerative colitis by the Medical Research Council, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p>£ million</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td colspan="6"><p>Crohn’s disease</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>3.1</p></td><td><p>3.4</p></td><td><p>2.6</p></td><td><p>2.4</p></td><td><p>2.5</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.8</p></td></tr><tr><td colspan="6"><p>Ulcerative colitis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>1.2</p></td><td><p>1.0</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.6</p></td><td><p>0.7</p></td><td><p>0.9</p></td><td><p>0.8</p></td><td><p>1.0</p></td></tr><tr><td colspan="6"><p>Crohn’s disease and ulcerative colitis</p></td></tr><tr><td><p>Medical Research Council<sup>1</sup></p></td><td><p>3.6</p></td><td><p>4.0</p></td><td><p>3.3</p></td><td><p>2.9</p></td><td><p>2.7</p></td></tr></tbody></table><p> </p><p><em>Note:</em></p><p> </p><p><sup>1</sup> Research looking at both Crohn’s disease and ulcerative colitis within the same project.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on research relating to the treatment of Crohn’s disease and ulcerative colitis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-03-25T12:50:09.563Zmore like thismore than 2015-03-25T12:50:09.563Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
523535
star this property registered interest false more like this
star this property date less than 2016-06-07more like thismore than 2016-06-07
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Reorganisation more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what accountability mechanics are in place related to decisions in Sustainability and Transformation Plan footprints. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 39795 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-06-14more like thismore than 2016-06-14
unstar this property answer text <p>Each Sustainability and Transformation Plan (STP) footprint is convened by a senior leader who has agreed to chair and lead the meetings on behalf of their peers. Each footprint has agreed its own governance and representation, depending on local circumstances and to ensure that all relevant National Health Service bodies and partners are included. An STP footprint supports organisations to come together to agree how best to improve and sustain services and health for their local populations.</p><p> </p><p>The local, statutory architecture for health and care remains. The arm's length bodies Regional Directors will retain accountability for delivery in their regions. Existing accountabilities for Chief Executives of provider organisations and Accountable Officers of Clinical Commissioning Groups are unchanged.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2016-06-14T10:30:36.977Zmore like thismore than 2016-06-14T10:30:36.977Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter
523539
star this property registered interest false more like this
star this property date less than 2016-06-07more like thismore than 2016-06-07
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Reorganisation more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what the legal status is of the changes to health and social care proposed in Sustainability and Transformation Plans. more like this
star this property tabling member constituency Oxford East more like this
star this property tabling member printed
Mr Andrew Smith more like this
star this property uin 39771 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-06-13more like thismore than 2016-06-13
unstar this property answer text <p>The Sustainability and Transformation Plans (STP) has no legal basis. Any plans submitted will be proposals that will form the basis for discussion. Depending on the level of local and national agreement, they may form the basis for further plans and actions that will be subject to the same legal and best practice requirements that govern the National Health Service.</p><p> </p><p>The local, statutory architecture for health and care remains, as do the existing accountabilities for Chief Executives of provider organisations and Accountable Officers of clinical commissioning groups. Organisations are still accountable for their individual organisational plans, which should form part of the first year of their footprint’s STP.</p><p> </p><p>The June STP submissions will be work-in-progress, and as such we do not anticipate the requirement for formal approval from boards and/or consultation at this early stage. Plans have no status until they are agreed. When plans are ready, normal rules around engagement and public consultation will apply.</p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN 39613 more like this
star this property question first answered
less than 2016-06-13T14:32:38.62Zmore like thismore than 2016-06-13T14:32:38.62Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
95
unstar this property label Biography information for Mr Andrew Smith remove filter